Ottobock SE & OBCK.DE
GermanyHealthcare · Medical Instruments & SuppliesXetra · EUR
80.38 EUR (+58.5%)
8 analysts
Trading 2120.00 €Open account ↗
XTB0.00 €affiliateOpen account ↗
eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗Trading 2120.00 €Open account ↗eToro0.86 €Open account ↗XTB0.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Ottobock SE & Co. KGaA is a German manufacturer of prosthetics, orthotics, and mobility solutions for people with disabilities, with a business model based on high-tech medical products and sales through specialized clinics and distributors.
Listed on Xetra · Symbol OBCK.DE · ETR: OBCK · Currency EUR
Key points
from its scores- ✓Strong growth8.3
- ✓High-quality business7.2
- ✕Poor share-price trend4.0
- ✕Unfavourable risk and backdrop4.5
- ✕Fragile balance sheet4.9
AI analysis
bottom line, main risk, context and newsQuality and growth are solid, but high debt and negative momentum suggest waiting for a better entry point.
Ottobock shows moderate financial health with net debt of 3.53x EBITDA, but exceptional quality (ROE 39.92%, operating margin 18.42%) and earnings growth of 306.8% justify its current valuation (forward P/E 13.97, PEG 0.40). Momentum is weak (26th percentile in 52 weeks), suggesting short-term caution.
Financial leverage (Net Debt/EBITDA of 3.53) is the main concrete risk, especially if the ECB continues raising rates and makes refinancing more expensive.
Context and risks
Ottobock operates in the medical devices sector, subject to moderate regulatory scrutiny in Germany and the EU, with product approval processes and healthcare reimbursement policies that can affect its margin. German institutional quality is high, so the penalty is mild and contained.
Is Ottobock SE & stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%).
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 25.0 | 26.7 | −7% |
| EV / EBITDA | 13.1 | 14.5 | −9% |
| Price / book | 8.2 | 4.1 | +99% |
| Price / sales | 1.9 | 3.4 | −45% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 6.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 80.38 EUR, +58.5% versus the price.
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 25.0
- Forward P/E
- 14.0
- EV / EBITDA
- 13.1
- Price / book
- 8.2
- Price / sales
- 1.9
- PEG
- 0.40
- Market cap
- 3.2B EUR
- Enterprise value
- 4.4B EUR
Profitability
- ROE
- 39.9%
- ROA
- 8.8%
- ROIC (approx.)
- 18.9%
- Gross margin
- 52.6%
- Operating margin
- 18.4%
- Net margin
- 7.4%
- Free cash flow
- 100.5M EUR
- FCF yield
- 3.1%
- Cash conversion
- 30%
Solvency
- Total debt
- 1.3B EUR
- Net debt
- 1.2B EUR
- Cash
- 93.6M EUR
- EBITDA
- 339.2M EUR
- Net debt / EBITDA
- 3.53
- Debt / equity
- 320.81
- Current ratio
- 1.23
- Quick ratio
- 0.64
Growth
- Revenue growth
- +9.6%
- Earnings growth
- +306.8%
- EPS (TTM)
- 2.03 EUR
- EPS (forward)
- 3.63 EUR
Dividend
- Dividend yield
- 1.9%
- Payout
- 48.3%
Risk and market
- Analyst consensus
- Strong buy (8)
- Target price
- 80.38 EUR
- 52-week range
- 45.56 – 65.00
Recent news
All OBCK.DE news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Ottobock SE &
Is Ottobock SE & stock cheap or expensive?
On P/E and EV / EBITDA, it trades in line with the Healthcare median (within 15%). Valuation score: 6.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 80.38 EUR, +58.5% versus the price. This is not investment advice.
What score does Ottobock SE & get on MeridIAn Screener?
It scores 6.1 out of 10, rank 921 of 2,130 (better than 55% of the companies analysed). Its strongest category is Growth (8.3) and its weakest, Momentum (4.0). Analysis of 08/10/2026.
What is Ottobock SE &'s P/E ratio?
Its P/E is 25.0: the share price equals 25.0 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 14.0.
How much is Ottobock SE & worth on the stock market?
Its market capitalisation is 3.2B EUR and its enterprise value, debt included, is 4.4B EUR.
How much debt does Ottobock SE & have?
Its net debt (debt minus cash) is 1.2B EUR. That is 3.53 times its EBITDA; the Healthcare median is 1.53.
Does Ottobock SE & pay a dividend?
Yes: its dividend yield is 1.91% and it pays out 48% of its earnings.
How has Ottobock SE & stock performed over the last year?
It has fallen 15.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 45.56 and 65.00 EUR. Past performance does not guarantee future results.
What do analysts think of Ottobock SE &?
8 analysts cover it; their average recommendation is “Strong buy” and their average target is 80.38 EUR (+58.5% versus the price). It is an estimate, not market data.